Shao-Lee Lin, Acelyrin CEO
Acelyrin sets out for a 2021-sized IPO for California biotech’s PhIII drug
Drug licensor and developer Acelyrin revealed more of its IPO plans Monday morning, mapping out what could be one of the biggest biotech IPOs in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
